RARE
Ultragenyx PharmaceuticalCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful readouts and regulatory progress validate pricing for niche indications, enabling meaningful re-rating and significant upside from current levels.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.9.
What can break
Clinical trial failure or negative topline
Momentum
40
Value
41
Sentiment
66
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $23.10 · Bull $46.20 · Bear $11.55
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-06 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $56.55
Why
Momentum40 · Δ7d -18.6
Value41 · Δ7d +0.1
Sentiment66 · Δ7d +5.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
40
34% active weight
Current posture
7d trendSoftening
Δ7d
-18.6
Δ21d
-32.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
66
33% active weight
Current posture
7d trendImproving
Δ7d
+5.9
Δ21d
+22.8
Why this grade
Composite grade C. Momentum 39.8 / Value 41.1 / Sentiment 65.8
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$2.36B
Beta
0.16
Shares Out
96.48M
P/E (TTM) · Derived
-4.2
P/S (TTM)
3.54
P/FCF (TTM) · Derived
-5.11
Rev YoY
+14.7%
EPS YoY
-29.3%
Gross Margin
+84.7%
Op Margin
-86.3%
Net Debt
$259.65M
Current Ratio
1.89
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology